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ABSTRACT

Transplanted murine bone marrow (BM) progenitor cells stimulate endogenous
beta cell proliferation and insulin production. To enrich for analogous human
progenitor cells, we purified human umbilical cord blood (UCB) and BM based on
high aldehyde dehydrogenase activity (ALDHhl), a conserved function in multiple
progenitor lineages. Transplantation of ALDHhl mixed progenitor cells or cultureexpanded multipotent stromal cells (MSC) into streptozotocin-treated NOD/SCID
mice revealed endogenous islet regeneration occurred via distinct mechanisms.
Transplantation of ALDHhl cells improved systemic hyperglycemia via increased
islet vascularization and proliferation resulting in increased islet size, but not islet
number. Contrary to mixed-progenitor cells, transplantation of cultured MSC
stably reduced hyperglycemia via an increase in islet number directly associated
with the ductal epithelium without evidence of NGN3+ endocrine precursor
activation. Further understanding of these endogenous angiogenic or putative
neogenic programs activated by distinct human progenitor subsets may provide
new approaches for combinatorial cellular therapies to treat diabetes.
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Chapter 1

Introduction

2
1.1 The Human Pancreas
The human pancreas is an organ composed of exocrine, ductal and endocrine
cells, and has two main functions: digestion and glucose homeostasis. Exocrine
cells, which compose 98% of the pancreas, are responsible for digestion, and
release a mixture of digestive enzymes and bicarbonate via pancreatic ducts into
the duodenum. The endocrine cells, which compose 1-2% of the pancreas, are
clustered throughout the exocrine tissue in islets of Langerhans, and release
hormones into the systemic circulation via the portal vein. The islets of
Langerhans were first described by Paul Langerhans in 1869, but their
involvement in endocrine secretion was not discovered until 1893 by Edouard
Laguesse (1).
Adult islets contain four major endocrine cell types: a-cells, (3-cells, 5-cells, and
PP cells, as well as more recently described Epsilon or Ghrelin cells (1) (Figure
1). The a-cells, which comprise 15-20% of the islet, secrete glucagon, a 29-amino
acid peptide with hyperglycemic action, into the circulation when low blood
glucose is detected. Upon release and binding to glucagon receptors on
hepatocytes, blood glucose levels are increased by stimulating breakdown of
stored glycogen (glycogenolysis) and by activating hepatic gluconeogenesis. (3cells compose the majority of the islet, representing 70-80% of the endocrine
cells. (3-cells uptake glucose through the GLUT2 transporter, sense blood glucose
levels, and secrete insulin, a 51-amino acid peptide with hypoglycemic action,
into the circulation when high blood glucose levels are detected. Upon insulin
release, insulin responsive cells in the peripheral tissues are stimulated to
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Figure 1. The endocrine cells of the islets of Langerhans. Schematic
representation of the pancreas containing the islets of Langerhans in which the
endocrine cells are clustered. In order to maintain glucose homeostasis, the a
cells secrete glucagon to increase blood glucose levels, and the (3 cells secrete
insulin to decrease blood glucose levels.
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uptake,

store and suppress the production of glucose. 5-cells secrete

somatostatin, an inhibitor of glucagon and insulin release. The least well-studied
endocrine cell in the pancreas is the PP-cell, which releases pancreatic
polypeptide (PP) following a protein-rich meal, fasting, or exercise. PP inhibits
gall bladder contractions and regulates pancreatic endocrine and exocrine
secretions (2, 3). The most recent hormone secreting cell to be discovered in the
pancreas, the Epsilon or Ghrelin cell, is thought to be important in growth
hormone release, metabolic regulation and energy balance, although it’s exact
role in the islet is not yet known (4).
1.2 Diabetes
The cells of the islets of Langerhans are responsible for the maintenance of
glucose homeostasis. Reduced ability of beta cells to produce insulin, or
resistance to insulin in peripheral tissue leads to a disruption in glucose
homeostasis and development of diabetes mellitus, a disease of which there are
two types: type 1 diabetes, also known as early onset or juvenile diabetes, and
type 2 diabetes, also known as adult onset diabetes (Figure 2).
1.2.1 Type 1 diabetes
Type 1 diabetes is an auto-immune disease where destruction of the insulin
secreting (3-cells is mediated by a cellular immune response. Although it may be
diagnosed at any age, type 1 diabetes is the most common auto-immune
disorder in childhood (5, 6), and accounts for 10% of diabetic patients. Incidence
rates in western countries is 8 to >50 per 100 000 individuals per year and the
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Figure 2. The mechanisms of type 1 and type 2 diabetes. Type 1 diabetes
is an autoimmune disease where pancreatic beta cells are destroyed leading
to reduced beta cell number and impaired insulin secretion. Type 2 diabetes
involves reduced sensitivity to insulin at insulin receptors on peripheral tissues,
impairing the uptake of glucose into tissues. Although different mechanisms
are involved that impair glucose homeostasis, both types of diabetes can lead
to sustained elevated blood glucose levels requiring intervention.
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prevalence in children under 14 is expected to rise to 1 million worldwide by 2025
(7).
In 1965, W. Gepts showed that the pancreata of patients with inflammatory
infiltrants (insulitis) contained lesions only in islets where some (3-cells were still
present. Islets without lesions were pseudoatrophic and contained only non-(3
endocrine cells. These seminal findings indicated that type 1 diabetes was an
inflammatory disease of autoimmune etiology (8). These inflammatory infiltrants
were later identified as mainly CD8+ T-cells and macrophages (9, 10), and could
be detected in patients at clinical presentation of type 1 diabetes (11).
Type 1 diabetes results from a combination of genetic and environmental factors.
The genes most associated with risk of type 1 diabetes are located in the HLA
class II locus on chromosome 6, however less than 10% of individuals with this
susceptibility develop diabetes (12). Environmental factors such as infectious
agents, dietary factors, and environmental toxins are also thought to trigger the
onset of diabetes in genetically predisposed individuals (13).
Prior to the discovery of insulin, patients with type 1 diabetes suffered from
severe hyperglycemia and ketoacidosis, became comatose and inevitably died.
However, poorly managed diabetes over extended periods of time is still
associated with many secondary complications that can be life threatening. It is a
leading cause of blindness, renal failure and limb amputation, as well as a risk
factor for heart disease and stroke (14).

7
1.2.2 Type 2 diabetes
Type 2 diabetes mellitus is a metabolic disorder characterized by resistance to
insulin action on glucose uptake in peripheral tissue, impaired insulin action to
inhibit hepatic glucose production, and dysregulated insulin secretion (14). Type
2 diabetes is increasing at an alarming rate and accounts for >90% of diabetic
cases. A worrisome trend is that this disease previously predominantly found in
adults is now widely diagnosed in children and adolescents, paralleling the
increase in childhood obesity (15). Up to 50% of newly diagnosed diabetic
children and adolescents in the US are diagnosed with type 2 diabetes (16).
Prolonged presence of type 2 diabetes is also accompanied by a decrease in (3
cell mass, due to increased p cell apoptosis, and is further exacerbated by
amyloid plaque deposits in the islets (17, 18). Susceptibility to insulin resistance
and defects in insulin secretion are at least partially genetically determined, and
the insulin-receptor substrates (IRS proteins), particularly IRS-2 may be involved,
since decreased IRS signaling leads to insulin resistance as well as (3 cell
apoptosis (19-21). IRS is important in promoting p cell survival (22) and
replication (23), however chronic hyperglycemia and hyperlipidemia found in type
2 diabetic patients, leads to IRS2 degradation and therefore p cell apoptosis (24,
25).
Environmental factors such as diet, physical activity and age play a large role and
interact with genetic predispositions in development of the disease. Obese
individuals will initially exhibit an increase in beta cell mass to compensate for the
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increased demand for insulin and obesity-associated insulin resistance, however
this adaptation eventually fails, leading to an overt type 2 diabetic state that must
be treated with insulin therapy (14, 17, 26, 27).
1.3 Insulin therapy
Insulin was first isolated and used clinically in 1923 by Banting, Best and Collip,
providing a major medical breakthrough for the treatment of diabetes (28, 29). In
1921 Banting and Best demonstrated that intravenous injections of extract from
dog pancreas, removed following 7-10 weeks of ductal ligation, reduced blood
glucose and sugar excreted in the urine in diabetic dogs. With the aid of Collip, ox
pancreatic extracts, were first administered into a diabetic patient at the Toronto
General Hospital on January 11, 1922. Although these first extracts were impure,
and caused adverse reactions, extracts were further purified by Collip by
removing inert material and precipitating the insulin, resulting in a purified extract
which worked successfully in decreasing the signs of diabetes in treated patients.
Animal-sourced insulin remained the standard until the first sythentic insulin was
produced in the early 1960s (30, 31). Synthetic human insulin became available
commercially in 1982 under the brand name Humulin. Home glucose monitoring
and self-administration of exogenous insulin became widely available in the
1970s (32) and remains effective treatment for many diabetic patients. Although
advances in blood glucose monitoring have been made, particularly with
continuous glucose monitoring systems (32), and continuous subcutaneous
insulin infusion (insulin pumps) (33, 34) this method of treatment remains
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insufficient for a small group of patients who experience life-threatening
hypoglycemic episodes with exogenous insulin therapy (35). Current treatment
for this subgroup of patients with brittle diabetes involves either whole pancreas
transplantation or islet transplantation.
1.3.1 Pancreas transplantation
Transplantation of cadaveric pancreata into diabetic patients, either as a single
organ transplant or in combination with kidney transplantation, can restore
euglycemia. Over 30 000 pancreata have been transplanted since the first
procedure was performed in 1966 (36, 37). In 1979 the first living donor pancreas
transplant using a segmental graft was performed and restored insulin
independence in the diabetic recipient (38). In 2008, 155 segmental pancreas
transplants from living donors were also reported and demonstrated advantages
over whole cadaveric pancreas transplants, such as closer HLA match, reduced
immunosuppression, and increased graft survival. This also lead to the much
needed expansion of the potential donor pool (39). However, living donor
transplants are not likely to become common practice as the pancreas is an
unpaired organ, and there are risks of serious organ-specific complications such
as pancreatitis, as well as possible deterioration of glucose metabolism in the
donor over their lifetime (40).
1.3.2 Pancreatic islet transplantation
As an alternative to whole pancreas transplant, allogeneic islet transplantation
has also been studied as a less invasive treatment for severe diabetics. The first
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islet transplantation was performed in 1990 (41), but since then, overall success
has been around 10% (42). In 2000, a landmark study from Edmonton showed
that 7 of 7 patients became insulin independent following islet transplantation
using a corticoid-free immunosuppressive regimen (43). This dramatically
increased the number of patients undergoing islet transplantation following this
newly developed protocol. In 2006, Shapiro et al published “International Trial of
the Edmonton Protocol for Islet Transplantation” in the New England Journal of
Medicine, revealing the successes as well as the many challenges and
shortcoming of this procedure. One year after transplantation, 44% of recipients
were still insulin independent, however only 1 of 36 subjects remained insulin
independent at 3 years. Islet transplantation remains a therapy limited to few
patients since there is a critical shortage of cadaveric islets available for
transplantation (many patients require islets from more than one donor), islets
lose their ability to function over time, and there are many adverse side effects
experienced due to immune-suppressant therapy (44). Future direction for the
treatment of diabetes is shifting from the replacement of whole pancreas, or
pancreatic islets, to the development of cellular therapies using stem cells for
beta cell replacement, or for the endogenous regeneration of beta cell function.
1.4 Stem cells
Stem cells, first identified in 1963, have two distinguishing features. They can
self-renew while remaining undifferentiated, and can differentiate into multiple cell
types (45) (Figure 3). Embryonic stem (ES) cells are pluripotent cells derived
from the inner cell mass of 4-5 day old embryos, that can proliferate indefinitely
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Figure 3. Differentiation of regenerative stem cells. Schematic of the
differentiation of human embryonic stem (ES) cells, induced pluripotent stem
(iPS) cells, and adult stem cells. ES cells and iPS cells can self-renew as
well as develop into cells of all 3 germ layers, including towards a beta cell
fate. Adult stem cells such as those found in bone marrow (BM) are typically
germ-layer specific in their differentiative ability, but contain stem and
progenitor cells of the hematopoietic (HSC), endothelial (EPC) and
mesenchymal (MSC) lineages, which can further differentiate into multiple
regenerative cell types.
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while maintaining the capacity to differentiate into cells of all three germ layers.
ES cells were initially isolated and cultured from mouse embryos in 1981 (46),
and then later from human embryos in 1998 (47). In contrast to pluripotent ES
cells, adult stem cells with multipotent differentiation ability are found in most
adult organs where their function may be to maintain and regenerate tissues after
damage. A newly developed type of stem cell, the induced pluripotent stem cell
(iPS cell), has been derived from human skin fibroblasts through retroviral
transduction of transcription factors Oct4, Sox2, c-myc, and Klf4 that modifies the
epigenetics and phenotype of the cells (48-50). iPS cells show pluripotency
similar to ES cells, including their ability to differentiate into all germ layers. There
are currently no approved therapies using ES or iPS cells due to difficulties in
directing the production of functional effector cells, and their undifferentiated
tumor (51), and teratoma forming capacity (52). In contrast, adult stem cells are
used for a growing list of medical procedures such as bone marrow
transplantation to treat hematopoietic malignancies.
1.5 Development of regenerative therapies for diabetes
There are currently two major initiatives underway to combat the beta cell
deficiency in diabetes: beta cell replacement, and endogenous beta cell
regeneration (53).
1.5.1 Cell replacement strategies for diabetes
1.5.1.1 Ex vivo expansion of adult beta cells
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Ex vivo beta cell expansion from donor pancreatic tissue to Increase the number
of beta cells available for transplantation Is currently under investigation. Beta
cells are however relatively quiescent and proliferate infrequently at a rate of
about 0.1-0.3%/day (54). Since under certain conditions, such as pregnancy,
beta cell mass can expand in vivo, it may be feasible to use external stimuli to
expand primary beta cells ex vivo. However, culturing human islets in serum free
media with growth factors such as FGF and HGF, GLP-1 (55), or overexpressing
nuclear protein p8 (56, 57), results in limited expansion (58) and beta cell
apoptosis. Beta cells of cultured islets have been reported to dedifferentiate,
expand, and redifferentiate, however these beta cells quickly lose their ability to
produce and secrete insulin. With insulin mRNA levels only 0.01% that of human
beta cells (59), this approach is currently limited as a feasible strategy to develop
large numbers of beta cells for transplantation into diabetic patients.
1.5.1.2 Derivation of beta cells from ES or iPS cells
ES and iPS cells may provide a promising therapy for the treatment of diabetes. If
these cells could be efficiently directed to a beta cell fate, customized patientspecific cellular therapy without the need for immune-suppressant therapy could
potentially be used to treat diabetic patients. However, a lack of reliable methods
of generating specific lineages from ES or iPS cells, and the risk that
transplantation of undifferentiated cells may produce teratomas, has limited the
use of these cells for therapy. Recently improvements have been made in
effectively differentiating ES cells towards the pancreatic lineage. In 2005,
D’Amour et al showed that ES cells could be differentiated into definitive
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endoderm cells (60), and then in 2006 that the definitive endoderm cells could be
differentiated into hormone expressing endocrine cells through a 5-step series of
directed intermediates similar to those that occur during embryonic pancreatic
development (61). Furthermore, these endoderm cells derived from human ES
cells were

shown to generate glucose-responsive endocrine cells after

transplantation into mice (62). However, although (3-like cells derived from ES
cells have shown the ability to reverse hyperglycemia when transplanted into
hyperglycemic NOD/SCID mice, this hyperglycemic correction was maintained for
less than 3 weeks, with insulin production lost while teratoma formation
progressed (52).
Like human ES cells, iPS cells also have the potential to differentiate into islet
like clusters through definitive and pancreatic endoderm, that release c-peptide
upon glucose stimulation (63). However, these protocols are still inefficient as
they produce heterogeneous cell populations with a low frequency of insulin
producing cells, and differentiated progeny that demonstrate only a fraction of the
insulin content found in endogenous beta cells. In addition, iPS protocols which
use retroviral or lentiviral-mediated expression of the necessary reprogramming
transcription factors, are currently not suitable for therapy due to the risk of
mutagenesis and tumorigenesis. Improvements in protocols to generate ¡PS cells
have been made that include non-integrating methods of gene delivery such as
plasmid transfection (64, 65), adenoviral transduction (66, 67), the piggyback
transposon system (68), or membrane-soluble reprogramming factors (69, 70).
However, clinical cell-replacement therapy for diabetes has not yet been
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achieved due to the continued obstacle of differentiating ES and iPS cells
towards fully mature endocrine cells.
1.5.2 Endogenous beta cell regenerative therapies for diabetes
In the context of regenerative therapies for the treatment of diabetes, the
potential contributions of transplanted stem cells are not limited to the direct
replacement of damaged beta cells (Figure 4). The repair of damaged islets or
the generation of new islets in vivo has also been proposed (53).
1.5.2.1 Bone marrow-derived stem cells
Adult, or post-natal stem cells can be obtained from several sources including
umbilical cord blood (UCB) and bone marrow (BM). These stem cells have the
potential to self-renew as well as develop into a wide range of regenerative cell
types serving as easily procured sources to facilitate repair of damaged or
diseased tissues (71). Human BM contains cells of the hematopoietic and
endothelial lineages involved in revascularization (72), as well as cells of the
mesenchymal

lineage,

involved

in

revascularization,

regeneration

and

immunomodulation (72, 73). An early study using transplanted mouse BMderived stem cells showed that these cells could differentiate in vivo into insulin
producing beta cells. Donor BM cells were able to specifically repopulate the
pancreatic islets without evidence of cell fusion with endogenous insulin
producing cells (74). However, similar experiments by several other groups did
not support this finding of transdifferentiation of BM cells into beta cells (75-77).
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Hess et al has previously shown that transplantation of murine BM-derived
mononuclear cells, or further purified c-kit+ progenitor cells, stimulate the
recovery of streptozotocin (STZ)-damaged islets by inducing proliferation of
recipient

beta

cells,

augmenting

glycemic

control

via the

endogenous

regeneration of beta cell function (75). Donor mouse cells with hematopoietic and
endothelial phenotypes were recruited to ductal regions, surrounded damaged
islets, and stimulated beta cell proliferation and insulin production in recipientderived beta cells. Several groups have extended these findings to show that islet
recovery can be induced by the induction of hematopoietic chimerism in overtly
diabetic NOD mice (78), and that simultaneous infusion of murine BM
mononuclear cells (MNC) with allogeneic mesechymal stem cells (MSC)
optimized islet repair and protection against T-cell mediated beta cell deletion
(79). Recently, Lee at al have shown that multiple high-dose intercardiac infusion
of human BM-derived MSC into STZ-treated immune-deficient NOD/SCID mice
have the ability to repair islets with minimal engraftment in the pancreas (73).
Thus, human MSC and other potentially regenerative BM-derived cell populations
represent an accessible population of expandable progenitors with regenerative
and immunomodulatory properties (80-82) for the development of regenerative
therapies for diabetes, with phase 2 clinical trials using MSC to treat recently
diagnosed type 1 diabetics currently being performed by Osiris Therapeutics.
1.5.2.2 MSC for islet regeneration
The International Society of Cellular Therapy defines mesenchymal stem cells, or
multipotent stromal cells (MSC) using three defining criteria: First, MSC are
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isolated in culture by plastic adherence, second, after culture >95% of cells
express CD73, CD90 (Thy-1), and CD105 (endoglin), but do not express
hematopoietic markers such as CD45, and third, MSC are able to differentiate
into multiple mesenchymal lineages (83). Specifically, they have multipotent
differentiate ability into osteocytes, adipocytes and chondrocytes in secondary
differentiation assays (84).
MSC migrate towards areas of damage and inflammation through their
expression of a variety of chemokine receptors and adhesion molecules. In vitro,
pancreatic islets attract MSC, mediated by CX3CL1-CX3CR1 and CXCL12CXCR4 interactions (85). This same group also confirmed MSC migration to
islets in vivo. MSC have also been shown to play an important role in modulating
the immune response. In damaged tissues, MSC are able to stimulate reduced Tcell (86) and B-cell proliferation (87), inhibit maturation as well as differentiation of
dendritic cells (88) and decrease the production of inflammatory cytokines by
immune cells (89). MSC can exert their effects by secreting immunosuppressive
molecules such as TGF-(3, IL-10, IDO and PGE2 (89). However, MSC require the
proper microenvironment, with a recent study finding that only MSC that had
exposure to activated T-cells displayed immunosuppressive effects (90), via the
induction of regulatory T cells (82). Exhibiting immunomodulatory effects and
having the capacity to escape immune recognition makes MSC an attractive cell
type to treat autoimmune or inflammatory diseases including type 1 diabetes (82).
MSC also contain properties that aid in the repair of damaged tissues. MSC may
modulate the microenvironment during injury and stimulate a shift from
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inflammatory response to a repair response (91). MSC also aid in repair through
exerting anti-fibrotic effects by secreting HGF and BMP-7 (92), and by stabilizing
vessels during neoangiogenesis to allow for adequate perfusion.
Phase 2 clinical trials are currently underway using intravenous infusion of the
drug PROCHYMAL®, in which the active ingredient is ex vivo cultured adult
human MSC, to treat patients with newly diagnosed type 1 diabetes. The trial,
performed by Osiris Therapeutics Inc in collaboration with the Juvenile Diabetes
Research Foundation, involves administration of 2x106 allogeneic MSC per kg
body weight at 3 time points 30 days apart. The aim of the study is to determine
whether transplanted MSC can protect the pancreatic tissue from further
autoimmune attack and/or repair damaged pancreatic tissue, and is expected to
be completed by December 2010.
1.5.2.3 UCB-derived stem cells for islet regeneration
In addition to the use of BM-derived stem cells or MSC, umbilical cord blood
(UCB) derived stem cells have also been proposed to support the endogenous
regeneration of beta cell function. In the past, clinical application of UCB-derived
stem cells has been limited to transplantation in the fields of hematology and
oncology, however an increasing number of studies support the use of these cells
for non-hematopoietic disorders, including diabetes (93, 94).
Advantages of UCB-derived stem cells include: 1.) non-invasive collection
procedure from the umbilical vein following separation of the umbilical cord from
the newborn, 2.) it is a readily available source due to over 100 million births
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worldwide annually (95), 3.) UCB Is isolated early in ontogeny, with UCB cells
having longer telomeres and containing telomerase activity (96), and 4.) UCB
cells demonstrate a lower incidence of graft-versus-host disease following
transplantation due to the lower number of T-cells, immaturity of B-cells and
decreased function of dendritic cells (97). In addition to being a rich source of
hematopoietic stem cells, UCB also contains endothelial progenitor cells (98)
similarly to BM. However, only 1 in 10 UCB samples contain MSC (99), a cell
type that is present in BM and has previously been implicated in beta cell
regeneration. Therefore differences between adult or post-natal stem cell sources
should not be overlooked when considering optimal cell source for therapy for
diabetes.
In vivo studies involving UCB cell transplantation into diabetic mice have shown
improvement in hyperglycemia and increased survival rates post-transplantation
(100) as well as delayed onset of autoimmunity and insulitis in a model of type 1
diabetes (101). Although the mechanisms by which UCB stem cells regenerate
the pancreas following transplantation are not yet known, in one study, insulinproducing cells of human origin were found in the islets of NOD/SCID mice
following intravenous transplantation (102). Some insulin producing cells
contained strictly human chromosomes, while other contained human and mouse
chromosomes, leading these authors to suggest that generation of insulinproducing cells can be mediated through fusion-dependent as well as fusion
independent mechanisms. A clinical trial using autologous UCB cells is currently
underway in children with recently diagnosed type 1 diabetes, who have
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autologous UCB stored (94). Thus far a slowing of the loss of endogenous insulin
production and enhanced glucose control has been reported, and found to be
due to a highly functional population of regulatory T cells (T-regs) within UCB
(103, 104). These Tregs are proposed to suppress activation of the immune
system and increase tolerance to self-antigens (94). Tregs preferentially localize
to the sites of inflammation (105, 106) where they suppress recruitment and
proliferation of effector T cells, and a decrease in frequency of naturally occurring
Tregs can contribute to the onset of autoimmune diabetes (107). Therefore, both
BM and UCB-derived cells partially function to improve and/or prevent
autoimmune diabetes by promoting generation or expansion of endogenous Treg
cells (82), or through provision of donor-derived Treg cells respectively. Thus,
human BM and UCB represent promising sources of stem cells for regenerative
therapy to treat diabetes in the future.
1.6 Endogenous pancreatic regeneration
The relevant mechanisms whereby the post-natal endocrine pancreas can
undergo repair or regeneration after various injury stimuli remain highly
controversial (Figure 5). In the healthy pancreas endogenous beta cell turnover is
low. However lineage tracing studies by Dor et al have established that after
partial pancreatectomy there is an increase in mature beta cell replication, and
this represents the primary mechanism responsible for restoring beta cell number
(108). In contrast several groups have suggested that beta cells can be
regenerated via islet neogenesis, the budding of new islets from the ductal
epithelia following partial pancreatectomy (109), or ductal ligation (110).
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Figure 5. Mechanisms of pancreatic regeneration following injury.
Following injury such as partial pancreatectomy, ductal ligation, or STZtreatment, several regenerative mechanisms have been suggested to
restore beta cell mass. Proliferation of remaining beta cells or neogenesis
from intra-islet Pdx1* pancreatic progenitors has been demonstrated.
Neogenesis from Pdx1+ or Ngn31 progenitor cells in ductal regions has
also been implicated in restoring beta cells.
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Although the existence and identity of a pancreatic progenitor cell have been
debated, Seaberg and colleagues have clonally isolated proliferative multipotent
pancreatic precursor cells from adult pancreatic islets and ductal regions (111).
Intra-islet PDX1+ precursors (112-114) and NGN3+ endocrine precursors
associated with the ductal lining have also been reported (115, 116).
Overexpression and ablation studies have shown that pancreatic endocrine
progenitor cells require transient expression of both PDX1 and NGN3 in
development (117, 118). PDX1 is expressed early in development in pancreatic
progenitor cells in the embryonic pancreatic ducts, differentiating towards both
endocrine and exocrine lineage (119). PDX1 is subsequently repressed until re
expression in mature beta cells. NGN3+ endocrine progenitor cells are a subset
of PDX1+ cells first appearing at embryonic day (E) 8.5, peaking at E15.5, and
becoming undetectable with hormone gene expression (120). NGN3+ cells are
unipotent committed cells, with each cell differentiating into only one endocrine
cell type.
In light of these current controversies, the regenerative programs activated during
islet recovery after STZ-mediated beta cell ablation and human progenitor cell
transplantation in vivo are largely uncharacterized and remain the key to
understanding endogenous beta cell regeneration.
1.7 Isolation of progenitor cell subtypes from UCB and BM
In order to specify the human progenitor cell lineages that facilitate the
regeneration of beta cell function after transplantation and to further investigate
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the potential endogenous regenerative mechanisms involved in immune-deficient
mice human UCB and BM stem cells were purified. With the exception of human
HSC expressing CD34, prospective purification of infrequent UCB- or BM-derived
stem cells for use in targeted regenerative therapy using cell surface markers is
currently ineffective because many nascent stem cell subtypes demonstrate the
absence of specific markers of differentiation in situ (121). Stem cell surface
markers also vary between species, stem cell source, lineage and cell cycle
progression during culture in vitro (122). In order to simultaneously isolate
progenitor cells from multiple lineages, these progenitors were purified based on
a conserved stem cell function, aldehyde dehydrogenase (ALDH) activity, an
enzyme highly expressed in primitive hematopoietic and neural progenitor cells.
In addition, ALDH1A1 activity is involved in intracellular oxidation of vitamin A to
retinoid acid, and implicated in the protection of long-lived cells from oxidative
stress (123, 124).
Relative ALDH activity can be detected using a fluorescent substrate for ALDH,
Aldefluor™ (124). Aldefluor™ is a Bodipy fluorochrome conjugated to an
aminoacetaldehyde (AAA) moiety, is uncharged and can freely diffuse across cell
membranes. Once in the cell, cytoplasmic ALDH1A1 converts Aldefluor™ into a
metabolized substrate that becomes trapped in the cell due to its negative
charge.

Under pharmacological

inhibition of the ABC transporters with

Aldefluor™ buffer, cells with high ALDH activity retain the Aldefluor™ and
fluoresce

(Figure

6).

The

integrity

and

function

of the

cell

are

not
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Figure 6. Isolation of stem cells based on aldehyde dehydrogenase
activity. Diffusion of Aldefluor™ reagent into mature and stem cells, where
only the stem cells contain high ALDH activity which converts the Aldefluor
into a negatively charged substrate, trapping it within the cell and causing the
cell to fluoresce. Stem cells can then be isolated using fluorescence
activated cell sorting.
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compromised by this procedure since upon removal of the Aldefluor™ buffer the
ABC transporters become reactivated and Aldefluor™ can be pumped out of the
cell returning the cell to it’s original state. Therefore, this procedure is clinically
applicable for the simultaneous enrichment of progenitor cells from the
hematopoietic (122, 125), endothelial (126) and mesenchymal lineages (72, 126)
for use in regenerative therapies. The amount of ALDH activity in a cell falls along
a spectrum from low ALDH activity to high ALDH activity, where cells with high
ALDH activity possess enriched progenitor function, are less committed to
differentiation, and maintain multipotency (122). In contrast ALDH10 cells contain
primarily mature T and B cells and demonstrate reduced colony forming capacity
(72).
We have recently shown that after hematopoietic reconstitution in sublethally
irradiated

NOD/SCID/MPSVII

mice,

hematopoietic

and

non-hematopoietic

progeny of transplanted human UCB-derived ALDHhl cells traffic efficiently to the
ductal and peri-islet regions of the pancreas (127) and transplantation of human
BM-derived ALDHhl progenitor cells promote endogenous revascularization in a
mouse model of critical limb ischemia (72). Thus, is was hypothesized that
transplantation of these prospectively purified mixed progenitor cells may also aid
in the regeneration or damaged islets via increased beta cell proliferation,
increased islet vascularization and increased insulin released systemically (128).
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1.8 Islet vascularization
Adequate islet vasculature is critical for maintaining glucose homeostasis due to
the high oxygen consumption of beta cells, as well as the need for timely
responses to changes in glucose concentrations and subsequent release of islet
hormones into the circulation. Islets have a dense capillary network that has been
shown to be 5-times higher than in exocrine tissue (129). Each beta cell is in
contact with at least one capillary, and they show polarity, with the secretory
granules being adjacent to the vessels to facilitate hormone release (130). Islet
capillaries also contain up to ten-fold more fenestrations than exocrine capillaries
due to the necessity of close interactions between endocrine cells and the
circulation. To ensure adequate islet capillary juxtaposition, pancreatic 3-cells
release VEGF-A, an angiogenic cytokine, which acts in a paracrine manner on
neighbouring endothelial cells to establish a network of fenestrated capillaries
(131) . Pancreatic endocrine cells can upregulate VEGF-A during islet formation
(132) , as well as following injury (133), to aid in hormone secretion. Therefore
transplantation of pro-angiogenic ALDHhl cells may stimulate increased islet
vascularization through further support of these endogenous processes.
1.9 Hypothesis and Objectives
The regenerative potential of UCB and BM-derived adult stem cells on islet
regeneration was investigated. The human source (UCB or BM) and cellular
populations (ALDHl0 or ALDHhl) most effective at regenerating endogenous islets
after transplantation into STZ-treated, immune-deficient recipients was sought to
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be determined. Moreover, the lineage-specific contributions of transplanted
progenitor subpopulations to support islet regeneration via putative pro
angiogenic or neogenic mechanisms were investigated.
It was hypothesized that human UCB and BM ALDHhl cells will establish
expandable cultures of hematopoietic, endothelial and mesenchymal lineages in
vitro. Due to the increased progenitor frequencies, it was further hypothesized
that transplantation of ALDHhl cells will mediate recovery from hyperglycemia in
immune-deficient mice with STZ-induced diabetes.
The first objective was to determine the in vitro colony forming frequency of UCB
and BM ALDHf0 and ALDHhl populations, and to establish expansion cultures of
mesenchymal lineages for future transplantation.
The second objective was to determine the capacity of UCB and BM ALDH10 and
ALDhf11 cells to improve beta cell function when transplanted into immunedeficient STZ-treated mice, and to investigate the mechanisms by which
transplanted cells augment beta cell function and insulin production.
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2.1

Progenitor cell isolation from human bone marrow and umbilical

cord blood. Human bone marrow (BM) samples (15 ml) were drawn from the
iliac crest with Informed consent from healthy allogeneic donors and human
umbilical cord blood samples (50 ml) were drawn with informed consent by
venipuncture of the umbilical vein following scheduled C-sections at the London
Health Sciences Centre, London, ON (Appendix 1). Samples were diluted with
PBS (1:2 for BM, and 1:1 for UCB) and layered onto Hypaque-Ficoll (Pharmacia
Biotech, Uppsala, Sweden) for centrifugation to isolate a layer of mononuclear
cells (MNC). MNC were removed and resuspended in lysis buffer (ammonium
chloride) to remove remaining red blood cells. MNC were then re-suspended in
Aldefluor™ buffer (StemCell Technologies, Vancouver, BC) and incubated with
Aldefluor reagent (5 pl/ml of cells) for 30-60 minutes at 37°C. Cells were
centrifuged and re-suspended in Aldefluor™ buffer for purification. ALDHl0 and
ALDHhl cells with low side scatter were selected by fluorescence activated cell
sorting (FACSVantage or FACSAria, BD Biosciences) at the London Regional
Flow Cytometry Facility. Following sorting, Aldefluor™ labeled cells were washed
with

PBS to remove accumulated fluorescent substrate by reactivating

transporters previously inhibited by Aldefluor™ buffer, leaving the cells in their
original state.
2.2 Progenitor Cell Assays. Human UCB and BM ALDHl0 and ALDHhl cell
populations were enumerated for human hematopoietic colony forming cell
(HCFC) activity following 10-12 days incubation in methylcellulose media
(Methocult® H4434, StemCell Technologies). ALDH|0 cells were plated at
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densities of 2x103 - 4x103 cells/well, and ALDHhl cells were plated at densities of
100 - 200 cells/well of a 12-well plate. Endothelial colony forming cell (ECFC)
activity and multipotent mesechymal stromal cell (MSC) activity were enumerated
by plastic adherence following 12-14 days incubation in endothelial growth media
(EGM-2 + Single Quots, Cambrex Biosciences, Inc., Walkersville, MD) and
Amniomax™

media

+ supplement

(Invitrogen,

Burlington,

ON,

Canada)

respectively. For non-hematopoietic colony formation, ALDH|0 cells were plated at
densities of 1x106 - 2x106 cells per T25 flask, and ALDHhl cells were plated at
densities of 1x105 - 3x105 cells per T25 flask (Figure 7). Single endothelial or
mesenchymal colonies were expanded in vitro for 2 passages and frozen in liquid
nitrogen for future expansion.
2.3 Progenitor cell transplantation into hyperglycemic immune-deficient
NOD/SCID mice. Adult (7-9 weeks) NOD/SCID (Jackson Laboratories, Bar
Harbour,

ME) mice were intraperitoneally (i.p.) injected with 35 mg/kg

streptozotocin (STZ) (Sigma-Aldrich) in citric acid buffer (CAB) daily for 5 days
(Day 1-Day 5) to induce hyperglycemia, or injected with CAB alone for
normoglycemic controls. Mice reaching hyperglycemia (3-5 fold baseline blood
glucose concentrations, or 15-25 mmol/L) by day 10, were sublethally irradiated
(300 cGy) and transplanted by tail vein injection with PBS as control, UCB- or
BM-derived MNC (20x106), ALDH10 (10x106) cells, or ALDHhi (2x105) cells, or
cultured

BM-derived

ALDH10 or

ALDHhl

MSC

(5x105).

Blood

glucose

concentrations were monitored by tail venipuncture weekly until day 42 using a
standard blood glucose monitor (Freestyle mini, Abbott Diabetes Care Inc,
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Alameda, CA) 24 hours prior to sacrifice, mice were i.p. injected with 200 pg of
EdU (Invitrogen, Burlington, ON) to label dividing cells (Figure 8).
2.4 Human cell engraftment of mouse tissues. Isoflurane anesthetized (Baxter
Corporation, Mississauga, ON) NOD/SCID mice were sacrificed on day 14, 17 or
42 (4, 7 or 32 days post-transplantation) by cervical dislocation. Blood was drawn
immediately from the left ventricle, allowed to clot at room temperature for 30
min, and centrifuged for 15 min at 1.5 ref to separate the serum layer. Serum was
removed and frozen for subsequent serum insulin quantification. The pancreas
was extracted and weighed, and the splenic portion of the pancreas was frozen in
optimal cutting temperature media (OCT, Tissue Tek, Sakura Finetek, Torrance,
CA). The remainder of the pancreas, the spleen, and a section of liver were
extracted and mechanically digested in 1 ml PBS with 5% FBS using a 16 gauge
needle and syringe. The BM was flushed from the femur and tibia. All digested
tissues were filtered, centrifuged, and re-suspended in PBS with 5% FBS before
being stained for the human cells using pan-leukocyte marker CD45 and HLAA,B,C, for 30 min and for 7-AAD to identify dead cells, prior to analysis of human
cell engraftment by flow cytometry (FACSCaliber, BD Biosciences). Engraftment
of human cells were compared to matched isotype controls (all BD Biosciences).
2.5 Immunohistochemistry and immunofluorescence. The splenic portion of
the pancreas was sectioned at 10 pm such that each slide contained 3 sections
150

pm

apart.

Pancreatic

sections

were

analyzed

by

colorimetric

immunohistochemistry for insulin^ beta cells to determine islet size, islet number
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Figure 8. Schematic of in vivo beta cell regeneration model. Immunedeficient NOD/SCID mice were i.p. injected with STZ for 5 days to induce
hyperglycemia. Hyperglycemic mice are sublethally irradiated and tail vein
injected with PBS or UCB or BM ALDH-purified cells, or BM-derived ALDHpurified MSC on day 10. Blood glucose was monitored weekly until day 42,
with EdU being administered 24 hours prior to sacrifice, and serum insulin
being collected at sacrifice on day 42 for subsequent analysis of islet
regeneration (Adapted from Hess et al., Nat Biotechnol, 2003).
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per mm2, and total beta cell mass. Immunofluorescence analysis was also
performed for insulin^ beta cells in islets, vWF+ endothelial cells in blood vessels,
CK19+ epithelial cells in ducts, NGN3+ endocrine progenitor cells, and Edll+
proliferating cells as detailed below. All tissues stained for immunofluorescence
were mounted in VectaShield with DAPI (Vector).
2.6 Quantification of islet size, number, and total beta cell mass. Frozen
sections were fixed in 10% buffered formalin (Sigma), washed in PBS, and
blocked with mouse-on-mouse reagent (Vector Labs, Burlingame, CA) and
peroxidase block. Mouse anti-mouse insulin antibody (1 in 1000 dilution, Sigma)
was detected with peroxidase labeled rabbit anti-mouse IgG antibody (1 in 500
dilution,

Vector)

and

ImmPACT

DAB

(Vector)

and

counterstained

with

hematoxylin. Size and number of islets were quantified by light microscopy
(Axioscope Z2, Zeiss, Germany) analyzing 4 areas (1 mm2) selected randomly
per section from a total of 3 sections per mouse using Northern Eclipse software.
Beta cell mass was calculated by [beta cell area/(total area - beta cell area)] X
pancreas weight.
2.7 Immunofluorescent islet blood vessel density quantification. For mouse
vWF+ endothelial cell detection, rabbit anti-mouse vWF antibody (1 in 200
dilution, Chemicon, Temecula, CA) was detected with fluorescein labeled goat
anti-rabbit IgG secondary antibody (1 in 200 dilution, Vector). For mouse insulin4
beta cell detection, mouse anti-mouse insulin antibody (1 in 1000 dilution, Sigma)
was detected with Texas Red labeled rabbit anti-mouse IgG antibody (1 in 200
dilution, Vector). Intra- and extra-islet blood vessel densities at day 42 were
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quantified

using fluorescence microscopy (Axioscope Z2, Germany) and

AxioVision software. vWF+ vessels per islet and vWF+ vessles per section area,
not including islet bound vessels, were quantified for 4 islets randomly selected
per section for each of 3 sections per mouse.
2.8 Immunofluorescent quantification of islet and duct association. To
quantify percentage of islet directly associated with ductal epithelium, pancreatic
tissue was stained with rabbit anti-mouse ck19 (1 in 200 dilution, Abeam Inc,
Cambridge, MA) and detected with fluorescein labeled goat anti-rabbit IgG (1 in
500 dilution, Vector) to identify ductal epithelial cells, and co-stained with anti
mouse insulin as previously described. Each islet in 3 pancreatic sections per
mouse was designated as either not associated with, or in direct contact with
CK19+ ducts at day 14, day 17 and day 42.
2.9 Immunofluorescent analysis of Ngn3+ endocrine progenitor activation.
Isoflurane anaesthetized pregnant NOD/SCID mice were sacrificed at 19 days
gestation by cervical dislocation. E19 mouse fetuses were dissected and
pancreata, brain and spinal cord were removed and frozen in OCT media.
Tissues were cryostat sectioned at 10 pm and stained as positive controls for
NGN3 expression. For mouse Ngn3+ progenitor cell detection, goat anti-mouse
NGN3 antibody (1 in 200 dilution, Santa Cruz Biotechnology, Inc., Santa Cruz,
CA) was detected with fluorescein labeled rabbit anti-goat IgG antibody (1 in
5000 dilution, Vector). BM-derived ALDH|0 or ALDHhl MSC transplanted mice
were stained for NGN3 at day 14, 17, and 42 to look for activation of endogenous
endocrine progenitor cells.
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2.10 Analysis of proliferating pancreatic cells. Mice were i.p. injected with 200
pg EdU 24 hours prior to sacrifice. EdU+ proliferating pancreatic cells were
detected using the Click-iT™ imaging kit (Invitrogen). Mouse testis were cryostat
sectioned at 10 pm and stained as positive control for a highly proliferative tissue.
Pancreata were co-stained for EdU and anti-mouse insulin or vWF as previously
described to identify dividing islets and vessels respectively. Percentage of
dividing beta cells was quantified by counting the number of EdU+lnsulin+ cells
per number of insulin+ cells in each of 3 sections per mouse.
2.11 Serum insulin quantification. Mouse serum insulin was quantified at day
42 (32 days post-transplantation) using mouse insulin ultra-sensitive EIA ELISA
kits (ALPCO, Salem, NH). 20 pi of serum was analyzed in duplicate per celltransplanted mouse, and compared to PBS transplanted control and CAB
injected normoglycemic control insulin levels.
2.12 Statistical Analysis. Data were expressed as mean ± standard error of the
mean (SEM). Analysis of statistical significance was performed using an unpaired
t-test for CFC frequencies, by two-way ANOVA for blood glucose data and by
one-way ANOVA followed by Tukey’s post-hoc test for all other analyses.
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3.1 Isolation of ALDH10 and ALDHhl cells from human UCB and BM. In order
to simultaneously purify cellular populations potentially enriched for multiple
progenitor phenotypes, we FACS-purified human UCB (Figure 9A) and BM
(Figure 9B) based on low side scatter, to remove granulocytes, and low versus
high Aldefluor ™ fluorescence. Cells with high ALDH-activity (ALDHhl) were rare
in human UCB (0.3±0.1%) and BM (0.8±0.2%), whereas cells with >5-fold lower
ALDH-activity (ALDH10) represented 34.3±2.6% of erythroid-depleted UCB or
8.2±1.3% of BM mononuclear cells (MNC) respectively. We have previously
shown

that

both

UCB-ALDHhi cells

(122),

and

BM-ALDHhi cells

(72),

demonstrated enriched expression of primitive cell surface markers (CD34,
CD133, c-kit), whereas ALDH10 cells demonstrated enriched expression of cell
surface markers of mature T-lymphocytes (CD3, CD4, CD8) and B-lymphocytes
(CD19, CD20).
3.2 UCB-derived ALDHhl cells were enriched for hematopoietic and
endothelial colony forming cells. In UCB samples, both ALDH10 and ALDHhl
cell populations contained hematopoietic colony forming cells (HCFC), capable of
forming colonies of erythroid (Figure 10A), macrophage and granulocyte
lineages. ALDHhl cells were enriched for hematopoietic colony forming cells (~1
HCFC in 4 cells) compared to ALDH10 cells (~1 HCFC in 7x103) (Figure 10C).
Similarly, both populations of cells contained endothelial colony forming cells
(ECFC) (Figure 10B), with ALDHhl cells being enriched (~1 ECFC in 4x104)
compared to ALDH10cells (~1 ECFC in 1x105) (Figure 10D). Neither ALDH10 nor
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Figure 9. Isolation of ALDH'° and ALDHhi
UCB and BM.

cell populations from human

Representative FACS sort plots for the isolation of cells from (A)

human umbilical cord blood (n=9) and (B) human bone marrow (n=8), with low
side scatter and low vs. high Aldefluor ™ fluorescence.
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Figure 10. UCB-derived ALDHhi cells were enriched for hematopoietic and
endothelial colony forming cells. Representative photomicrographs of (A)
hematopoietic, (B) endothelial, and (C) mesenchymal colonies 14 days following
plating of UCB-derived ALDH'1' cells under hematopoietic, endothelial, or
mesenchymal growth conditions respectively. (D) UCB-derived ALDHhl cells are
enriched for hematopoietic colony forming cells (n=4). (E) UCB-derived ALDHh‘
cells are enriched for endothelial colony forming cells (n=4). (F) UCB-derived
ALDH10 and ALDHhi cells were devoid of mesenchymal colony forming cells
(n=4) (NC= No Colonies). Scale bar = 200pm for hematopoietic colonies, and
500pm for endothelial colonies. Data represent mean ± SEM (*P<0.05,
*‘ P<0.01).
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ALDHhl UCB-derived populations established mesenchymal colonies (MCFC) in
UCB samples isolated by venipuncture.
3.3 BM-derived ALDHhl cells were enriched for hematopoietic, endothelial
and mesenchymal colony forming cells. Similar to UCB-derived cells, BMderived ALDH10 and ALDHhl cell populations could establish hematopoietic
colonies of erythroid (Figure 11 A), macrophage and granulocyte lineages, with
the ALDHhl cells being enriched for HCFC (~1 HCFC in 8 cells) compared to the
ALDH10 cells (~1 HCFC in 2x103 cells) (Figure 11D). ALDH10 and ALDHhi BMderived cells also contained ECFC (Figure 11B) and MCFC (Figure 11C), with
ALDHhl cells being enriched for ECFC (~1 ECFC in 1x103) compared to ALDH10
cells (~1 ECFC in 4x105) (Figure 11E), as well as being enriched for MCFC (~1
MCFC in 1x103) compared to ALDH10 cells (~1 MCFC in 3x104) (Figure 11F) in
lineage selective media in vitro. Collectively, these analyses suggest that both
UCB- and BM-derived ALDHhl cells contain progenitors with putative pro
angiogenic functions (72), whereas human BM-derived ALDH10 or ALDHhl cells
also contained expandable MSC, previously implicated in islet regeneration (73).
3.4 Transplantation of UCB- or BM-derived ALDHhl cells reduced blood
glucose in STZ-treated hyperglycemic mice. To evaluate the capacity of
human UCB or BM progenitor cells to restore islet function after injury, STZtreated (35 mg/kg/day, days 1-5) hyperglycemic (15-25 mmol/L at day 10)
NOD/SCID mice were intravenously injected with human ALDH10 cells (10x106),
ALDHhl cells (2x105) or MNC (20x106) at day 10 and blood glucose
concentrations were monitored until day 42. Cell doses were chosen according to
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Figure 11. BM-derived ALDHhi cells were enriched for hematopoietic,
endothelial, and mesenchymal colony forming cells. Representative
photomicrographs of (A) hematopoietic, (B) endothelial, and (C) mesenchymal
colonies 14 days following plating of BM-derived ALDHhl cells in hematopoietic,
endothelial or mesenchymal growth conditions. Scale bars = 200pm. (D) BMderived ALDHhl cells were enriched for hematopoietic colony forming cells (n=4).
(D) BM-derived ALDHhl cells were enriched for endothelial colony forming cells
(n=4). (E) BM-derived ALDHhl cells were enriched for mesenchymal colony
forming cells (n=4). Data represent mean ± SEM (*P<0.05, *‘ P<0.01).
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the availability of sorted cell populations and the relative frequencies of progenitor
colony formation in vitro. Compared to PBS-injected controls that remained
severely

hyperglycemic

(24.4±2.9

-

31.9±2.1

mmol/L)

after

day

17,

transplantation of 10x106 UCB-derived ALDH10cells lead to a temporary reduction
in hyperglycemia (18.1 ±1.9 mmol/L) at day 17, with a gradual return of equivalent
hyperglycemia from days 21-42 (Figure 12A). Transplantation of 50-fold fewer
(2x105) UCB-derived ALDHhl cells induced a modest but lasting relative reduction
in hyperglycemia (18.4±1.8 - 23.2±3.1 mmol/L) from days 17-42 (Figure 12A).
Interestingly, mice transplanted with low-dose (2x105) ALDH10 cells (24.2±3.4 3.5±3.4 mmol/L, n=5), or 20x106 unpurified UCB MNC (20.9±2.4 - 26.1±2.8
mmol/L, n=9) did not improve hyperglycemia compared to PBS controls (Data
now shown).
Mice transplanted with equivalent doses of human BM-derived cells showed a
similar pattern of hyperglycemic reduction. Transplantation of BM-derived ALDH10
cells transiently reduced hyperglycemia at day 21 (17.3±2.4 mmol/L) and 28
(21.5±3.1 mmol/L) compared to temporally matched PBS controls (Figure 12B).
Likewise, transplantation of BM-derived ALDHhl cells induced significant and
stable reductions in hyerglycemia (16.0±2.1 - 20.1 ±3.6 mmol/L) from days 17-42.
For serum insulin concentrations at day 42, all STZ-injected mice showed
reduced serum insulin compared to citric acid buffer (CAB)-injected vehicle
controls (**P<0.01, Figure 12, C and D). Compared to PBS controls (0.04±0.01
ng/ml), only BM-derived ALDHhl cell transplanted mice had increased serum
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Figure 12. Transplantation of UCB- or BM-derived ALDHhi cells reduced
blood glucose in STZ-treated hyperglycemic mice. Compared to PBStransplanted controls (n=7), mice transplanted with (A) UCB ALDH'0 cells (n=9)
had temporarily reduced hyperglycemia at day 17 with subsequent return of
hyperglycemia while mice transplanted with UCB ALDHhl cells (n=7) had stably
reduced hyperglycemia from day 17-42. (B) Mice transplanted with BM ALDH'0
cells (n=10) had transiently reduced hyperglycemia days 21-28, while mice
transplanted with BM ALDHhl cells (n=8) had stably reduced hyperglycemia.
(E-F) At day 42, only STZ-treated mice transplanted with BM-derived ALDHhi
cells had increased serum insulin compared to PBS controls. Data represent
mean ± SEM (*P<0.05, **P<0.01, ***P<0.001).
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insulin (0.22±0.05 ng/ml) at day 42 (Figure 12D), corresponding to the observed
decreases in blood glucose concentrations. Thus, BM-ALDHhl cell transplantation
stably reduced systemic hyperglycemia and increased serum insulin. Collectively,
transplantation of low-dose ALDHhl cells was more effective than high-dose
ALDH10 cells at sustaining glycémie control, and BM-derived ALDHhl cells were
superior to UCB-derived ALDHhl cells in terms of the magnitude of improved
hyperglycemia and serum insulin release.
3.5 Engraftment of human cells into recipient mouse BM and pancreas. To
promote human hematopoietic reconstitution after transplantation, hyperglycemic
NOD/SCID mice were sub-lethally irradiated (300 cGy) on day 10 prior to human
UCB- or BM-derived cell transplantation. CD45+/HLA-A,B,C+ human cell
engraftment in recipient mouse BM and pancreas was detected by flow cytometry
(Figure 13 A and B). There was robust human hematopoietic reconstitution at day
42 after transplantation with equivalent doses (2x105) of ALDHhl cells from UCB
(28.0±6.0%) or BM (12.0±3.0%) (Figure 14 A and B). In contrast, 50-fold higher
doses (10x106) of ALDH10 cells from human UCB or BM did not consistently
engraft recipient BM (Figure 14A and B).
Pancreatic damage due to pre-treatment with multiple low-dose STZ injections
has previously shown to increase pancreas recruitment of murine BM cells after
hematopoietic progenitor cell transplantation (75). Despite high levels of human
hematopoietic reconstitution, intravenously injected ALDHhl cells from human
UCB showed inconsistent (4 or 9 transplanted mice) and low frequency (<0.4%)
human hematopoietic (CD45+) cell engraftment in the murine pancreas (Figure

47
B

Figure 13. UCB and BM ALDHhl cells engraft recipient mouse bone
marrow. Representative flow cytometric quantification of human cell
engraftment at day 42 in the BM and pancreas of recipient mice intravenously
transplanted with 10x106 ALDH10 or 2x105 ALDHh' cells from human (A) UCB
or (B) BM. ALDHhi cells from both sources highly engrafted recipient BM, and
had low levels of engraftment in recipient pancreas, while ALDH10cells did not
engraft recipient tissues.
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B

Figure 14. Transplantation of human ALDHhi cells resulted in significant
human hematopoietic chimerism in mouse BM.

Transplantation of 2x10s

ALDHhl cells from human (A) UCB or (B) BM into sublethally irradiated STZtreated NOD/SCID mice highly engrafted recipient murine BM. ALDH10 cells
did not engraft recipient BM. (C-D) Transplantation of human ALDHhl cells
from BM, but not UCB resulted in consistent human cell engraftment in
recipient mouse pancreata.
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14C). BM-derived ALDHhl cells consistently (5 of 6 transplanted mice) engrafted
the

recipient

pancreas,

however

human

cell

frequency

remained

low

(0.23±0.01%), and pancreas engrafted human cells were largely hematopoietic
(Figure 13B). Transplanted ALDH10 cells from human UCB or BM were rarely
detected in the mouse pancreas at day 42 (Figure 14, C and D), indicating that
transplanted human ALDHhl cells showed enhanced engraftment in the injured
mouse pancreas, albeit at low frequencies.
3.6 Early recruitment of human cells to injured murine pancreata. To
address the initial recruitment of human cells to the injured pancreas at the time
of hyperglycemia reduction, STZ-treated mice were transplanted with 10x10
ALDH10or 2x105 ALDHhl cells at day 10 and euthanized at day 14 or 17. At 4 days
post-transplantation (day 14), human cells were not detected in the pancreas of
mice transplanted with either ALDH10 (n=3) or ALDHhl (n=3) cells. By 7-14 days
post-transplantation, human cells were detected at low frequency (<0.1% human
cells) in 5 of 6 mice transplanted with ALDHhl cells compared to only 1 of 8 mice
transplanted with ALDH10 cells. Although low frequency human ALDHhl cell
recruitment to the pancreas was sufficient to observe improved hyperglycemia,
more efficient delivery and improved survival of progenitor cells in the pancreas
may be required to further improve glycémie control.
3.7 Transplantation of ALDH-purified cells increased endogenous islet size,
but not islet number. Although we have previously established that transplanted
murine BM progenitor cells stimulate endogenous islet recovery (75), the
mechanisms

by which

transplanted

human

progenitor

cells

support

a
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regenerative niche in the pancreas remain uncharacterized. To further investigate
the

role of endogenous

islet regeneration after human

progenitor cell

transplantation in STZ-treated mice, the pancreata of control and transplanted
mice were stained for murine insulin (Figure 15) and analyzed for islet number
(Figure 16A), islet size (Figure 16B) and total beta cell mass (Figure 16C),
revealing increased islet size following ALDH-purified mixed progenitor cell
transplantation.
To confirm severe pancreatic damage at day 10, multiple low-dose STZ
administration induced approximately 10-fold reduced islet number (0.16±0.03
islet/mm2), and a 2-fold reduced islet circumference (225±25 pm), compared to
CAB injected vehicle controls. Over the 32 day post-transplantation period, STZtreated mice injected with PBS at day 10 increased islet number approximately 3
fold (0.54±0.10, *P<0.05), without significant increase in mean islet size (198±18
pm), indicating that endogenous islet recovery could be detected without
corresponding control of hyperglycemia (Figure 12 A and B). Compared to CABinjected normoglycemic mice, islet number remained 2-fold lower and mean islet
size was significantly decreased at day 42 (P<0.05, Figure 16, A and B).
Compared to PBS-injected controls, transplantation of UCB- or BM-derived
ALDH|0 or ALDHhl cells had no effect on overall islet number at day 42 (Figure
16A), however there was a significant increase in islet size following UCB ALDHl0
or ALDHhl cell transplantation, to 273±22 pm and 266±17 pm respectively (Figure
16B). Mean islet size was further increased following BM ALDHl0 or ALDHhl cell
transplantation to 337±42 pm and 390±33 pm respectively, and equivalent to
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Figure 15. Transplantation of ALDH-purified UCB- or BM-derived cells
increased

islet

size

in

STZ-treated

recipients.

Representative

photomicrographs of insulin* islets at day 42 in mice injected with (A) citric acid
buffer (CAB) vehicle (upper), or STZ (35mg/kg, days 1-5) followed by
transplantation at day 10 with PBS (lower), (B) UCB ALDH10or ALDHhl cells, or
(C)

BM ALDH'0 or ALDH*1' cells. Scale bars = 200pm.
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Figure 16. Transplantation of BM-derived ALDHhi cells increased islet
size and total beta cell mass in STZ-treated recipients. Compared to
PBS-transplanted controls (n=10), mice transplanted with UCB ALDHi0
(n=7), UCB ALDHhi (n=7), BM ALDH'0 (n=7) or BM ALDHhl (n=7) cells
showed (A) equivalent islet numbers, and (B) increased islet size. (C) Mice
transplanted with BM ALDHhl cells showed increased total beta cell mass
compared to PBS controls. Data represent mean ± SEM (*P<0.05,
**P<0.01).
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baseline islet size in CAB-treated control mice (358±40 |jm). As an overall
indication of islet recovery, transplantation of BM ALDHhl cells significantly
increased total beta cell mass to 0.50±0.09 mg, compared to PBS controls at
0.14±0.01

mg (Figure

16C).

Collectively, only human

BM ALDHhl cell

transplanted mice demonstrated increased islet size correlated with increased
total beta cell mass, augmented serum insulin levels, and prolonged glycémie
control.
3.8 Transplantation of ex vivo expanded MSC from independent BM
samples showed variable capacity to reduce hyperglycemia. Lee et al., has
previously shown that intercardiac injection of dual bolus human BM MSC
improved hyperglycemia via the endogenous repair of pancreatic islets and renal
glomeruli after low-dose STZ-treatment in NOD/SCID mice (73). Since human
BM-derived ALDH|0 and ALDHhl populations contained cells with mesenchymal
colony forming capacity (72), whereas analogous human UCB cells did not
(Figure 10E), and human BM cells were superior to human UCB cells in the
magnitude of hyperglycemic correction (Figure 12, A and B), we sought to further
investigate the capacity of ex vivo expanded ALDHl0 or ALDHhl MSC to improve
hyperglycemia after transplantation.
Clonally established ALDHl0 or ALDHhl MSC lines from 6 independent BM
samples were expanded for 3-5 days in ex vivo culture, and transplanted into
hyperglycemic NOD/SCID mice as a single bolus of 5x105 MSC at day 10. After
initial screening, transplantation of ALDH-purified MSC showed donor dependent
variability in the capacity to improve hyperglycemia (Table 1). Independent of
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Table 1. ALDH'° and ALDHhl MSC from independent BM samples showed
variable capacity to reduce hyperglycemia. Transplantation of 5x105 ALDH10 or
ALDHh BM-derived MSC from 6 independent BM samples into hyperglycemic
immune-deficient NOD/SCID mice (A) reduced blood glucose, or (B) did not reduce
blood glucose from day 17-day 42 compared to (C) PBS controls. Data shown as
mean ± SD. (*p<0.05, **p<0.01, ***p<0.001).
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whether the MSC were initially derived from ALDH10 or ALDHhl cells, mice
transplanted with expanded MSC from 3 independent human BM samples
(BM12, BM17, BM20) showed consistent reductions in hyperglycemia (Table 1A),
whereas ALDH10 or ALDHhl MSC from 3 alternative human BM samples (BM16,
BM18, BM21) showed no capacity to reduce hyperglycemia (Table 1B) when
compared to PBS-injected matched controls (Table 1C).
In order to fully characterize MSC-induced islet regeneration, we selected BM18
(Figure 17A) and BM20 (Figure 17B) to represent non-regenerative and
regenerative samples respectively. Although BM18 ALDH-purified MSC did not
reduce hyperglycemia after transplantation (Figure 17A), mice transplanted with
BM20 ALDH10 or ALDHhl MSC showed significantly reduced hyperglycemia
between day 17 - day 42 (Figure 17B). Transplantation of both BM20-derived
ALDH10 (0.30±0.10 ng/ml) or ALDHhl MSC (0.32±0.05 ng/ml) significantly
increased serum insulin at day 42 compared to BM18-derived MSC (0.08±0.04
ng/ml) or PBS-injected controls (0.04±0.01 ng/ml, P<0.01) (Figure 17C). Similar
to previous findings by Lee et al (73), the functional capacity to improve
hyperglycemia was independent of permanent MSC engraftment in the pancreas,
where human cells were not detected by FACS at day 42.
3.9 Prolonged expansion of ALDH-purified MSC diminished hyperglycemic
reduction after transplantation. In order to quantify the effect of expansion on
MSC capacity to impact islet regeneration, highly regenerative ALDHhl MSC from
BM20 were expanded for 2-4 passages, 5-6 passages, or 7-8 passages, prior to
transplantation into hyperglycemic recipients. Each expanded MSC cohort

Time (days)

Time (days)

c

Figure 17. Transplantation of ex vivo expanded ALDH10 or ALDHhi MSC
reduced hyperglycemia and increased serum insulin in STZ-treated
recipients. (A) Transplantation of ex vivo expanded ALDH'0 (n=7) or ALDH11'
(n=6) MSC from BM18 did not reduce hyperglycemia compared to PBS
controls (n=8). (B) Transplantation of ex vivo expanded ALDH10 (n=6) or
ALDHhi (n=7) MSC from BM20 improved hyperglycemia compared to PBS
controls (n=7). (C) Compared to BM18-derived MSC transplanted mice or
PBS transplanted controls, mice transplanted with BM20-derived ALDH10 or
ALDH11' MSC showed increased serum insulin. Data represent mean ± SEM
("P<0.01, "*P<0.001).
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possessed similar viability (>90%) at harvest, expressed characteristic MSC
surface markers (>95% CD90+, CD105+, CD73+), and retained multipotent
capacity for adipocyte, osteocyte, and chondrocyte formation in differentiation
cultures

(data

not shown).

Despite

no evidence

of population-specific

differentiation or senescence in vitro, prolonged expansion of ALDHhl MSC
diminished their capacity to improve hyperglycemia after transplantation (Figure
18). As shown previously, transplantation of early passage (P2-P4) ALDHhl MSC
showed robust and prolonged hyperglycemic reduction from day 21 - day 42
(15.5±2.3 - 18.3±2.9 mmol/L) compared to PBS-injected controls (25.1 ±1.5 31.0±1.7 mmol/L). In contrast, transplantation of late passage (P7-P8) ALDHhl
MSC did not produce hyperglycemic reduction (24.1±4.0 - 29.0±1.6 mmol/L),
whereas

transplantation

of

P5-P6

ALDHh'

MSC

induced

intermediate

hyperglycemic reduction (16.2±2.4 - 23.2±2.3 mmol/L) (Figure 18). Collectively,
endogenous islet regeneration observed after MSC transplantation was BM
sample-dependent, and prolonged MSC expansion prior to transplantation
decreased the magnitude of hyperglycemic reduction.
3.10 Transplantation of ex vivo expanded MSC increased endogenous islet
number but not islet size. In contrast to mice transplanted with uncultured
ALDH-purified cells from human UCB or BM that showed an increase in islet size
but not islet number (Figure 17, A and B), transplantation of BM20-derived
ALDH10or ALDHhl MSC increased insulin^ islet density at day 42 to 0.80±0.09 and
0.82±0.10 islets/mm2 respectively compared to PBS-injected controls (0.50±0.08
islets/mm2, Figure 19A). However, regenerating islet size was similar to PBS-
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Time (days)

Figure 18. Prolonged expansion of ALDH-purified MSC diminished
hyperglycemic reduction after transplantation. Mice transplanted with
BM20 ALDHn' MSC showed diminished capacity to reduce hyperglycemia
with prolonged ex v/Vo expansion from P2-P4 to P7-P8. Data represent
mean ± SEM (*P<0.05, **P<0.01, ***P<0.001).
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Figure 19. Transplantation of ex v iv o expanded MSC increased
endogenous islet number but not islet size. Compared to BM18derived MSC transplanted mice and PBS transplanted controls, mice
transplanted with BM20-derived early passage ALDH'0 or ALDHhi MSC
showed (A) increased islet number, (B) equivalent islet size, and (C)
increased total beta cell mass. Data represent mean ± SEM (*P<0.05).
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injected controls (Figure 19B). As predicted by the lack of blood glucose
correction, transplantation of analogous BM18-derived MSC did not increase islet
number (Figure 19A) or islet size (Figure 19B). For BM20 ALDH'° or ALDHhl
MSC, islet recovery led to a 10-fold increase in total beta cell mass to 0.6±0.2
ng/ml and 0.50±0.06 ng/ml respectively compared to PBS-injected controls at
0.05±0.09 ng/ml. Thus, the recovery of islet function could occur by increased
islet size with uncultured ALDH-purified progenitors, or by an increase in islet
number with cultured ALDH|0 or ALDHhl MSC, and the stimulation of these distinct
programs was mediated by the characteristics of the progenitor populations
administered. Therefore, we next sought to characterize how specific human
progenitor subpopulations support endogenous islet recovery via the potential
stimulation of islet angiogenesis or beta cell proliferative programs.
3.11

Transplantation

of

human

ALDHhl cells

induced

islet-specific

vascularization. The efficient coordination of new blood vessel formation is
essential for many regenerative processes. In the regenerating adult pancreas,
glucose-sensitive insulin secretion into the islet vasculature is a prerequisite to
improved systemic hyperglycemia. Since transplanted human BM ALDHhl
progenitor cells have been shown to support capillary formation in a model of
acute hindlimb ischemia (72), we postulated that reduced hyperglycemia (Figure
12) and increased islet size (Figure 16) after human ALDHhl cell transplantation
would be complemented

by progenitor-stimulated islet angiogenesis. To

investigate islet vascularization after the transplantation of UCB- or BM-derived
progenitor populations, pancreata of transplanted mice were co-stained for insulin
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Figure 20. Transplantation of ALDHhi progenitor cells increased islet
vascularization

in

STZ-treated

recipients.

Representative

photomicrographs of vWF* vessels associated with insulin4 islets 42 days
after injection of (A) CAB vehicle (upper), or STZ (35mg/kg/day, days 1-5)
followed by transplantation at day 10 with PBS (lower), (B) 10x106 UCB
ALDH10 or 2x105 ALDHhl cells, and (C) 10x106 BM ALDH10 or 2x105 BM
ALDHhl cells. Arrows mark vWF4 microvessels within islets. Scale bars =
50pm.
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and von Willebrand factor (vWF) at day 42 (Figure 20). vWF was used as a
specific marker of functional endothelial cells within islet microvessels in vivo
(72). CAB-injected (2.0±0.6 vWF+ vessels/islet) and STZ-injected (2.1 ±0.8 vWF+
vessels/islet) control mice showed equivalent islet microvessel density at day 10,
indicating that STZ-treatment did not initially target microvasculature in spite of
significant beta cell damage. At day 42 islet vascularization in PBS-injected
controls was further decreased to 1.0±0.2 vWF+ vessels/islet, whereas islet
vascularization in mice transplanted with UCB-derived ALDHhl cells was
increased to 2.8±0.4 vWF+ vessels/islet, and transplantation of BM-derived
ALDFI10 cells (3.3±0.7 vWF+ vessels/islet) or BM-derived ALDHhl cells (5.5±0.7
vWF+ vessels/islet) further augmented regenerating islet vascularization (Figure
21 A). Induced vessel formation in the transplanted mouse pancreas was isletspecific as extra-islet pancreatic tissue vascularization was unchanged after
transplantation of ALDFI10or ALDFIh' cells from either human source (Figure 21B).
3.12 Transplantation of BM-derived ALDFI10 or ALDFIhl MSC did not increase
vascularization. In contrast to the improved islet vascularization following
transplantation of freshly isolated ALDHhl cells from human UCB or BM,
transplantation of ex vivo expanded ALDFI10 or ALDHhl MSC from BM18 or BM20
did not augment vWF+ microvessel density (Figure 22). Compared to PBS
controls, neither intra-islet vasculature (Figure 23A) nor extra-islet vasculature
(Figure 23B) were significantly increased following MSC transplantation. These
data indicated that the transplantation of UCB- or BM-derived ALDH-purified
progenitor cells, but not ex vivo expanded MSC, activate an islet-specific
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Figure 21. Transplantation of pro-angiogenic ALDHhi progenitor cells
into STZ-treated mice increased intra-islet vascularization.

(A)

Compared to PBS controls (n=6), mice transplanted with UCB ALDH11'
(n=5), BM-derived ALDH'0 (n=7), or BM-derived ALDHhi cells (n=8)
increased vascularization within islets. (B) Transplantation of UCB ALDH10
or ALDHni cells, or BM ALDH10 or ALDHhl cells, did not increase overall
pancreas (extra-islet) vascularization. Data are shown as mean ± SEM
(*P<0.05, *“ P<0.001).
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Figure 22. Transplantation of ex vivo expanded human ALDH10 or
ALDHhi MSC did not increased islet vascularization. Representative
photomicrographs of vWF* blood vessels associated with insulin* islets at
day 42 after injection of STZ (35mg/kg/day, days 1-5) followed by
transplantation at day 10 with (A) 5x105 ex vivo expanded ALDH0 or
ALDHhl MSC from BM18. or (B) 5x105 ex vivo expanded ALDH'° or ALDHhl
MSC from BM20. Arrows mark vWF* microvessels within islets. Scale bars
= 50pm.
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Figure 23. Transplantation of ex vivo expanded ALDH10 or ALDHhi MSC
had no impact on intra-islet or extra-islet vascularization. (A)
Compared to PBS controls, mice transplanted with BM18- or BM20-derived
MSC did not increase vascularization within islets. (B) Transplantation of
BM18- or BM20-derived MSC did not increase overall pancreas (extra
islet) vascularization. Data shown are mean ± SEM.
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angiogenic program resulting in increased islet vascularization and release of
insulin into the circulation, thereby improving glycémie control.
3.13 Transplantation of ALDHhl progenitor cells induced proliferation of
vWF+ vessels. To further investigate the increased vascularization of murine
islets following transplantation of UCB- or BM-derived ALDHhl cells, we analyzed
EdU incorporation into proliferating cells within vessels at day 17 and day 42. In
PBS-injected controls, proliferating cells associated with vWF+ blood vessels
were rare, indicating a slow turnover of endothelial cells within blood vessels after
STZ-damage (Figure 24A). However, representative photomicrographs at early
(day 17) and late (day 42) time points showed numerous proliferating vWF+
endothelial cells following UCB- or BM-derived ALDHhl (Figure 24B) cell
transplantation, confirming the induction of endothelial cell activation and
sustained blood vessel remodeling. However, transplantation of ex vivo
expanded ALDHl0 or ALDHhl MSC from regenerative marrow samples (BM20) did
not stimulate significant microvascular cell proliferation, with EdU incorporation in
endothelial cells similar to PBS-injected controls (Figure 24C).
3.14 Transplantation of ALDHhl progenitor cells induced proliferation of
insulin+ islets. Although alternate modes of beta cell expansion through islet
neogenesis have recently been proposed (116), the established mechanism
responsible for islet regeneration in the STZ-damaged adult pancreas is through
induced proliferation of surviving beta cells (108). To investigate the increased
islet size following UCB- or BM-derived ALDHhl cell transplantation, we analyzed
EdU incorporation into proliferating cells within the islets at the earliest
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Figure 24. Transplantation of ALDHhi mixed progenitor cells induced
rapid proliferation of vWF+ vessels in STZ-treated mice. Representative
photomicrographs of Edll-labeled proliferating cells associated with vWF+
blood vessels at day 17 (upper) or day 42 (lower) after STZ injection (35mg/
kg/day, days 1-5) and transplantation at day 10 with (A) PBS, (B) 2x105 BM
ALDHh\ or (C) 5x105 ex vivo expanded BM20 ALDHhl MSC. Mice
transplanted with BM ALDHhi cells showed extensive proliferation of vWF+
vessels by day 17 that was maintained until day 42. PBS and MSC
transplanted mice showed minimal proliferation directly associated with the
vWF' vessels. Scale bars = 20pm.
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observation of blood glucose Improvement (day 17, 7 days post-transplantation)
and at the end of our 42-day protocol (32 days post-transplantation). Edil
incorporation within insulin+ islets after transplantation of UCB or BM-derived
ALDHhl cells revealed numerous EdU+ beta cell nuclei per islet at day 17 (Figure
26A), and EdlT proliferating beta cells were still detected in large islets out to day
42 (Figure 25B) (Figure 26B). PBS-injected control pancreata did not contain
EdU-labeled insulin^ beta cells within islets at early or late time points (Figure
25A) (Figure 26). Together these data indicate the early stimulation (within 7
days) and sustained beta cell proliferation was associated with the systemic
administration of UCB- or BM-derived ALDHhl progenitor cells. EdU+ and insulin+
cells were also observed within small islets or adjacent to single beta cells 7 days
following ALDH'° or ALDHhl MSC transplantation (Figure 25C) (Figure 26A), but
no islet bound EdU+ cells were detected at later time points (day 42) (Figure
26B). Thus, increased islet size and vascularization following ALDHhl cell
transplantation could be attributed to the stimulation of increased beta cell and
endothelial cell proliferation respectively, while modest but unsustained beta cell
proliferation observed after transplantation of BM MSC resulted in numerous,
small islets with arrested beta cell proliferative potential.
3.15 Transplantation of ALDH-purified MSC increased islets associated with
ck19+ ducts. We next sought to determine the mechanisms by which ALDHpurified MSC contribute to the endogenous regeneration of islet function. Since
transplantation of BM20-derived ALDH10 or ALDHhl MSC increased islet number
(Figure 19A), without extensive or prolonged beta cell proliferation (Figure 25C),
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Figure 25. Transplantation of ALDHhi mixed progenitor cells induced
proliferation of murine insulin* islets in STZ-treated mice. Representative
photomicrographs of EdU-labeled proliferating cells associated with insulin*
islets at day 17 (upper) or day 42 (lower) after STZ-injection (35mg/kg/day,
days 1-5) and transplanted at day 10 with (A) PBS, (B) 2x10s BM ALDHhl
cells, or (C) 5x105 BM20 ALDHhi MSC. PBS injected mice showed no
proliferation within insulin* islets at day 17 or day 42. Mice transplanted with
BM ALDHni cells showed beta cell proliferation within islets at day 17 and was
still present at day 42. Mice transplanted with BM ALDHh‘ MSC showed beta
cell proliferation within islets at day 17 only. Arrows mark proliferating cells
within islets. Scale bars = 20pm.
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Day 42

Figure 26. Transplantation of UCB and BM ALDH-purified cells induced
sustained beta cell proliferation. (A)

Compared to PBS controls which

showed no proliferation of beta cells at day 17, mice transplanted with UCB
or BM ALDH'0 or ALDHhi cells, or BM20 ALDH!o or ALDHhi MSC had increased
beta cell proliferation. (B) Compared to PBS controls which showed no
proliferation of beta cells at day 42. mice transplanted with UCB or BM
ALDH'0 or ALDHhl cells had increased

beta cell

proliferation.

Mice

transplanted with BM20 ALDH10 or ALDHhl MSC had no beta cell proliferation
at day 42. (n=3-4).
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we postulated that new islet formation may be stimulated in ductal regions
following MSC transplantation. Since previous studies have reported islet
neogenesis in ductal regions (116) (53) (110), we analyzed the association of
regenerating islets with CK19+ ductal epithelial cells at day 17 and day 42 after
BM20 ALDHl0 or ALDHhl transplantation. Representative photomicrographs show
insulin^ islets were in direct contact with CK19+ ductal structures at 7 and 32 days
after ALDHl0 (Figure 27A) or ALDHhl (Figure 27B) MSC transplantation.
Compared to PBS-injected controls at 7 days post-transplantation where only
5.0±0.8% of islets were directly associated with CK19+ ducts, there was a
significant increase in islets with direct contact to CK19+ductal epithelia following
regenerative ALDHl0 (41.0±8.3% of islets) or ALDHhi (22.5±1.1% of islets) MSC
transplantation (Figure 28A). The significant increase in islet and duct association
following ALDH10 or ALDHhl MSC transplantation was maintained for >1 month
post-transplantation, at 18.5±2.7% and 20.2±1.5% respectively, however, no
increase in islet association with ducts was observed following UCB- or BMderived ALDH-purified progenitor cell transplantation at day 17 (Figure 28A) or
day 42 (Figure 28B). Some regenerating islets associated with ducts also
contained CK19+ cells (Figure 27A) suggesting putative interplay between ductal
resident endocrine precursors and regenerating islets. Nevertheless, the ductal
region represents a potential niche for endogenous islet regeneration after MSC
transplantation.
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Figure 27. Transplantation of BM-derived ALDH'° or ALDHhi MSC
increase

islet

association

with

ck19+

ducts.

Representative

photomicrographs of insulin* islets associated with ck19* ductal structures
at day 17 (upper) or day 42 (lower)

in STZ-treated mice after

transplantation at day 10 with 5x105 BM20-derived (A) ALDH'0 or (B)
ALDHhi MSC and stained for mouse insulin and the ductal epithelial
marker ck19. Arrows mark ck194 cells within islets. Scale bars are 50pm.
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Figure 28. Increased islet/duct association at day 17 and day 42
following transplantation of BM20-derived ALDH'° or ALDHhi MSC.
(A) Compared to PBS controls, mice transplanted with BM20 ALDH'0
(n=4) or ALDHhi (n=4) MSC had significantly increased islets associated
with ducts at day 17. (B) Compared to PBS controls, mice transplanted
with BM20 ALDH10 (n=5) or ALDHhi (n=5) MSC had significantly
increased islets associated with ducts at day 42. Data are mean ± SEM
(*P<0.05, **P<0.01).
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3.16 Transplantation of BM-derived MSC did not activate Ngn3 expression.
Previous studies of islet regeneration have suggested that similar to embryonic
development, islet neogenesis could be mediated from endocrine progenitor cells
to restore beta cell mass (109) (110). Furthermore, Xu et al has shown that newly
formed islets in ductal regions arise from NGN3+ endocrine precursor cells after
ductal ligation (116). To further characterize regeneration in ductal or islet regions
after the transplantation of human MSC, we stained murine pancreata for insulin
and NGN3 at several time points throughout the regeneration process (day 14,
17 and 42). NGN3 is expressed by endocrine progenitor cells during embryonic
development, appearing first at embryonic day (E) 8.5, peaking at E15.5, and
becoming undetectable at birth (120). Representative photomicrographs show
nuclear localization of NGN3-expression was abundant in E18.5 pancreas
(Figure 29A, upper panel). However, in the adult pancreas, NGN3-expression
was absent at day 10 in mice pre-treated with STZ (Figure 29A, lower panel),
demonstrating that STZ-treatment alone did not activate NGN3 expression.
Although insulin expression was induced in ductal regions as early as day 14,
immunofluorescent microscopy did not detect activation of endogenous NGN3expression in islets or ducts at day 14, day 17 (Figure 29, B and C) or day 42
following ALDH'° or ALDHhl MSC transplantation. Similarly, transplantation of
UCB or BM-derived ALDH-purified cells did not activate endogenous NGN3
expression in recipient pancreas. In contrast to the induction of endogenous
angiogenic and

beta cell

proliferative

programs characterized after the

transplantation of BM-derived ALDHhl progenitor cells, transplantation of ALDH-
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Figure 29. Transplantation of BM-derived ALDH'° or ALDHhi MSC did not
activate Ngn3-expression in the pancreas of STZ-treated recipients. (A)
Representative photomicrographs of embryonic day 18.5 pancreas (upper) as a
positive control for Ngn3 expression, and STZ injected mice at at day 10 prior to
cell transplantation (lower). (B) Representative photomicrpgraphs of STZ
injected (35mg/kg/day, days 1-5) mice transplanted at day 10 with BM ALDH'0
MSC and stained for insulin and Ngn3 showed no detectable Ngn3‘ cells in the
pancreas at day 14 (upper) or 17 (lower). (C) Representative photomicrographs
of STZ-injected (35mg/kg/day, days 1-5) mice transplanted at day 10 with BM
ALDHhi MSC and stained for insulin and Ngn3 showed no detectable Ngn3*
cells in the pancreas at day 14 or 17. Scale bars are 20pm.
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purified MSC specifically augmented the formation of small islets associated with
CK19+ ducts, without increased islet vascularization or sustained beta cell
proliferation. Taken together, these data suggest that islet regeneration in STZtreated mice after human MSC transplantation was consistent with the induction
of an endogenous neogenic program, but without transition through an Ngn3expressing endocrine precursor.
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Chapter 4

Discussion
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4.1 Summary
The primary objective of this research was to investigate the mechanisms
underlying endogenous islet regeneration after the transplantation of clinically
relevant human progenitor cell populations. Transplantation of uncultured human
ALDHhl cells or culture-expanded human ALDH'° or ALDHhl MSC into STZtreated, hyperglycemic NOD/SCID mice showed that activation of distinct islet
regenerative programs was dependent on source and lineage-restriction of the
progenitor cells administered. UCB and BM-derived ALDHhl mixed progenitor
cells

contained

pro-angiogenic

progenitor

subtypes

(72)

that

following

transplantation into hyperglycemic NOD/SCID mice stimulated beta cell and
endothelial cell proliferation leading to increased islet size and vascularization.
BM ALDHhl transplant recipients had a subsequent increase in total beta cell
mass, serum insulin levels, and a stable reduction of systemic blood glucose.
These findings supported the hypothesis that ALDHhl cells will mediate recovery
from hyperglycemia following STZ-induced diabetes.
Although transplantation of culture-expanded MSC derived from independent BM
donors showed variable capacity to improve hyperglycemia, transplantation of
culture-expanded BM-derived ALDH'° or ALDHhl MSC from selected regenerative
lines permanently reduced blood glucose via an alternative mechanism. Whereas
the freshly isolated mixed progenitor cells reduced hyperglycemia through an
increase in islet size and vascularization, cultured MSC did not significantly
stimulate proliferative or pro-angiogenic programs, but increased beta cell mass
and serum insulin release through an increase in islet number, a large proportion
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of which were directly associated with the ductal epithelium. Although NG3+
endocrine precursors have been identified in ductal regions after ducal ligation
(116), we did not observe NGN3 activation after cell transplantation in STZtreated recipients. These divergent mechanisms are summarized in Figure 30.
We have identified that endogenous islet regeneration can occur by the
stimulation of mature beta cell proliferation associated with islet specific
angiogenesis, or by the formation of new islet structures in ductal regions
suggestive of a neogenic regenerative mechanism.
4.2 ALDH-purified mixed progenitor cells initiate islet vascularization
We have previously shown that BM ALDHhl cells contain pro-angiogenic
progenitor cells capable of inducing revascularization of ischemic limbs following
transplantation in a mouse model of acute limb ischemia, by transiently homing to
the damaged tissue and stimulating endogenous blood vessel regeneration (72).
Without integrating into recipient vasculature, tail vein injected human ALDHhl
cells migrated specifically to the ischemic tissue and stimulated endogenous
capillary formation resulting in the recovery of blood flow after femoral artery
ligation. Here we showed that UCB- and BM-derived ALDHhl cells similarly
enhanced islet-specific vascularization in the STZ-treated mouse pancreas.
Increased vascularization was specific to the islets, rather than extra-islet
pancreatic tissue, suggesting that STZ damage to beta cells, followed by ALDHhl
cell transplantation was required to optimally induce islet angiogenesis. Damaged
tissues secrete growth factors which promote recruitment of hematopoietic and
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Figure 30. Distinct mechanisms for endogenous islet regeneration
following transplantation of human ALDHhi cells or ex v iv o cultured
MSC. Schematic of the divergent mechanisms involved in pancreatic
regeneration after progenitor cell transplantation. Transplantation of ALDHhl
mixed progenitor cells augmented islet size and vascularization through
increased beta cell and endothelial cell proliferation. Transplantation of ALDHpurified MSC induced an increase in islet number associated with ck19‘
ducts, suggesting that the mechanism involved in pancreatic regeneration
depends on the transplanted population of cells initiating regeneration.

81
endothelial progenitor cells to areas of damage where they may promote and
sustain endogenous angiogenesis (133). Islet- derived beta cells (134), and
pancreatic ductal cells (135), are known to secrete angiogenic growth factors
such as VEGF and chemokines such as stromal derived factor 1 (SDF-1) that
promote recruitment of proangiogenic cells to areas of pancreatic damage, where
they initiate angiogenesis (136). Interestingly, increased islet vascularization was
also associated with increased beta cell turnover and islet hyperplasia, which
ultimately contributed to improved hyperglycemia and increased total beta cell
mass after transplantation of BM-derived ALDHhl cells. Thus, the pro-angiogenic
progenitor subtypes contained within freshly isolated UCB- and BM-derived
ALDFIhl populations are also implicated in the induction of beta cell proliferation
via paracrine interaction (72). Further study of the cellular communication at the
islet microvascular and beta cell interface during islet regeneration is warranted
to uncover potential target molecules that stimulate endogenous beta cell
proliferation and islet vascularization.
4.3 Potential role of human MSC in islet revascularization
In addition to hematopoietic and endothelial cells, MSC contained within the BM
ALDHhl cell population may also support revascularization. MSC have recently
been shown to have a perivascular origin in situ, and cultured CD146+
perivascular

cells

exhibited

osteogenic,

chondrogenic

and

adipogenic

differentiation potentials, and expressed characteristic stromal cell surface
markers after culture (CD73, CD90, CD105) (137). In vitro, BM-MSC can stabilize
tubule formation in a pericyte-like manner, and release both angiogenic and
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stabilizing factors, which act on the vasculature in a paracrine manner, facilitating
vessel formation (138). In in vivo implants, adipose-derived MSC also function as
perivascular cells, where they wrap endothelial cell-formed functional blood
vessels and stabilize the vascular network (139, 140). Thus, MSC work in concert
with other progenitor subtypes to promote vascularization, as implants of
endothelial and adipose progenitors together produced a density and complexity
of vascular structures much higher than implants of either cell type alone (140).
When injected as a singular lineage specified by ex vivo culture, transplantation
of human MSC alone did not augment islet-specific vascularization. However,
human BM-derived ALDHhl cells possessed enriched multipotent mesenchymal
colony forming cell capacity in vitro (72), and the most potent islet vasculogenic
potential after transplantation, suggesting that enhanced islet function after
transplantation of BM-derived ALDHhl cells may be synergized by paracrine
regenerative or pro-angiogenic stimuli provided by nascent MSC administered
within the ALDHhl mixed progenitor population. We hypothesized that the
resulting return of hyperglycemia over time following UCB ALDHhl transplantation
may be due to the lack of MSC in this source of progenitor cells. UCB ALDHhl
cells containing only EPC and HSC may form less stable neo-vessels that lose
their function over time. The presence of MSC in the transplanted BM ALDHhl cell
population may co-ordinate angiogenesis through direct contact with newly
formed vessels, or through the secretion of pro-angiogenic factors, the later of
which is supported by our model which shows limited engraftment of transplanted
MSC in the recipient mouse pancreas. Increased vascularization of damaged
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islets is essential to allow for delivery of nutrients and regenerative stimuli to
maintain viability of regenerating tissue, and to allow for secretion of produced
insulin into the circulation.
4.4 Potential role of human MSC in islet regeneration
Transplantation of human MSC into STZ-treated mice has previously been shown
to reduce blood glucose concentrations via an uncharacterized mechanism (73).
Here we show that ALDH-purified MSC had a greater ability to significantly and
permanently reduce blood glucose compared to the previously studied unpurified
MSC. In addition, we showed that there is sample dependent variability in the
capacity of transplanted MSC to stimulate endogenous beta cell regeneration,
and that early passage MSC were required in order to obtain maximal blood
glucose reduction. Extended passage of regenerative MSC clones showed
diminished capacity to reduce hyperglycemia after transplantation, warning that
the islet regenerative activities of human MSC may be compromised by
expansion in serum rich media under atmospheric oxygen tension (141, 142).
Although, MSC did not appear to change phenotypically with increasing passage,
it has been reported that there are major differences between early and late
stage cultures of MSC, with cell cycle genes upregulated early, and subsequent
upregulation of cell development genes at later stages, which may impact their
regenerative capacity (143). Nevertheless, optimization of lineage-specific
progenitor cell isolation and expansion require further development to assure
efficient delivery of the appropriate paracrine stimuli to induce islet regeneration.
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Similar to previous findings by Lee et al which have shown that transplanted MSC
possess significant capacity to regenerate islets with only minimal long-term
engraftment

in the

pancreas

(73),

we

observed

significantly

improved

hyperglycemia after ALDH-purified MSC transplantation, but did not detect
significant human cell engraftment in the recipient mouse pancreas at one week
and one month after MSC transplantation, further suggesting that in our model
MSC act to enhance endogenous regeneration through paracrine mechanisms.
Similarly, in murine transplantation models for cardiac regeneration after infarct,
transplanted MSC improve cardiac function via secretion of anti-inflammatory or
pro-angiogenic mediators without long-term cardiac engraftment (144, 145). After
tail vein injection, adherent MSC accumulate in the pulmonary capillaries of the
lungs (146). Although some MSC have previously been shown to migrate to islet
and ductal regions following STZ-treatment (73, 85) our data strongly suggests
that in our model MSC may act from distant site to exert subsequent paracrine or
hormone action in the pancreas. However, the specific factors secreted by MSC
that are involved in islet regeneration are yet to be determined and remain the
key to fully understanding transplantation-induced endogenous islet regeneration.
Robust beta cell proliferation and sustained islet development appeared
attenuated following the initial formation of new islets. Thus, more efficient
delivery of regenerative MSC directly to the pancreas to initiate cell-cell contact
dependent regeneration, or increased survival of delivered MSC at ectopic sites,
may improve the efficiency of endogenous islet recovery. One alternative strategy
to improve delivery and retention of MSC in damaged tissues may be to culture
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MSC under low oxygen conditions, which upregulates CXCR4 and CX3CR1
expression, enhancing migration of MSC in response to SDF-1a in vitro and
enhancing MSC engraftment in vivo (141).
4.5 Human MSC enhance endogenous islet formation via a novel neogenic
mechanism
Several lines of evidence support that human MSC augment endogenous islet
regeneration via a novel post-natal islet neogenic mechanism. Neogenesis is
defined as the formation of new islets from endocrine precursor cells in the
pancreas. During embryonic development, all pancreatic exocrine and endocrine
cells differentiate from the ductal epithelium. Previous studies of pancreatic
regeneration suggested that similarly to embryonic development, new islets are
formed from endocrine progenitor cells in ductal regions to restore beta cell mass
following partial pancreatectomy (119, 147). Neogenesis has been previously
documented to occur rapidly in several steps following injury: proliferation of the
ductal epithelium, dedifferentiation to a multipotent pancreatic progenitor, and
subsequent directed differentiation into endocrine, acini or mature duct cells,
where differentiation of the specific cell types was mediated by external stimuli
(148). We found a significant increase in the number of islets associated with the
ductal epithelium following MSC transplantation into our STZ-treated mice,
suggesting MSC could possibly act to stimulate differentiation of ductal progenitor
cells to islet cells in order to regenerate the damaged pancreas. However, the
identity of these endocrine progenitor cells remains elusive. We did not observe
evidence of NGN3+ progenitor cell activation in ductal regions as noted in studies
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of islet neogenesis by Xu et al employing ductal ligation (116). NGN3 is
expressed transiently by endocrine progenitors during embryonic pancreas
development, and it cannot be ruled out that NGN3 was not expressed very
briefly during MSC-stimulated regeneration. Alternatively, the increased number
of islets may have differentiated from PDX1+ progenitors in ductal regions as
noted after partial pancreatectomy (147), however PDX1 detection in our STZ
model was suboptimal (data not shown).
Evidence supporting that islets may be derived from the ductal epithelial cells
following MSC transplantation was the continued presence of CK19+ cells in
several duct-associated islets. During islet neogenesis from the ductal epithelium,
transitional cells can express both CK19 and insulin, and some beta cells in
newly developing islets express duct cell markers not normally expressed in
mature beta cells (147, 149). Another possibility is that the ductal region may act
as a regenerative niche that is stimulated to support the regeneration of islets
following MSC transplantation, possibly through activation of insulin'PDX1+ intra
islet beta cell precursors, which have previously been shown to escape STZdeletion and repopulate damaged islets (112). Thus, intra-islet precursors in ductassociated islets may be preferentially activated to restore beta cell mass
following MSC transplantation. Furthermore, ductal epithelial cells have been
shown to produce VEGF and interleukin-8 (135), angiogenic cytokines or
chemokines reported to have beneficial effects on islet survival in rodent
transplantation models (150). Therefore islet regeneration in ductal regions may
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be partially supported and maintained by the initiation of regenerative stimuli
provided by CK19+ ductal epithelial cells.
4.6 Clinical Implications
Our data outlines several clinically applicable regenerative therapies for the
treatment of diabetes. Autologous human BM or allogeneic human UCB
progenitor cells can be isolated in a clinically relevant manner using ALDHactivity, and ALDH-purified MSC are amenable to ex vivo expansion to increase
regenerative cell numbers. However, serum free expansion conditions that do not
result in diminished regenerative capacity require further development.
In order to be a plausible therapy for type 1 diabetes, the issue of continued auto
immune destruction of regenerated beta cells must be addressed. The
immunomodulatory properties of MSC, and their ability to escape immune
recognition make them a cell type of interest. Phase II clinical trials by Osiris
Therapeutics Inc, transplanting allogeneic MSC into newly diagnosed type 1
diabetics are currently underway and are expected to be complete by the end of
2010. In addition to MSC, clinical trials are also being performed with autologous
UCB-derived cells, a source containing T regulatory cells, which may further
protect beta cells from auto-immune destruction.
A challenge with treating diabetes using endogenous beta cell regenerative
strategies may be the requirement of some remaining endogenous beta cells. In
patients with advanced type 1 diabetes, beta cell mass may be too low to
endogenously regenerate to a sufficient level to reduce hyperglycemia. In these

88

cases, an exogenous source of beta cell may first need to be administered,
followed by in vivo expansion and maintenance using endogenous regenerative
strategies.
Transplantation of ALDH-purified mixed progenitor cells or MSC may also be a
possible therapy for type 2 diabetic patients, who do not have auto-immune
destruction of beta cells, but rather have decreased beta cell mass and insulin
resistance. Although diet and exercise is still a necessity, and the issue of insulin
resistance would need to be addressed, these cells could aid in restoring beta
cell mass and increase insulin available to help meet metabolic demand.
There are several limitations to our study and it’s application for clinical treatment
of diabetes. While type 1 diabetic patients have autoimmune destruction of their
pancreatic beta cells leading to hyperglycemia, our model involved chemical
destruction of pancreatic beta cells to induce hyperglycemia in NOD/SCID mice,
an immune-deficient model. Therefore beta cell regeneration is being studied in
an environment free of continued autoimmune attack of the regenerating beta
cells. Furthermore, although it is beneficial to study the transplantation of stem
cells from human sources, as these would be the cells studies in clinical trials, the
function of transplanted human cells into a mouse model is not fully
representative of their potential regenerative capacities when transplanted into
humans due to species incompatibilities.

89
4.7 Future Direction
It is essential to determine the origin of regenerating islets, and investigate the
regenerative cytokines and chemokines secreted by the transplanted ALDHpurified mixed progenitor cells and MSC to understand the complexity of the
regenerative niche and more efficiently direct regeneration. Expanding MSC in
low oxygen conditions, and transplanting directly into the pancreas may further
improve regeneration by maintaining MSC in a less differentiated state and
enabling contact-dependent regeneration in addition to paracrine supported
regeneration.
To address auto-immunity, studies could be performed in NOD mice, which
spontaneously develop diabetes, to assess the ability of ALDH-purified murine
BM cells or MSC to protect against immune-development of diabetes, as well as
to regenerate the damaged islets and provide subsequent protection from auto
immune

deletion.

In addition,

it can

be

investigated

whether

multiple

transplantations of MSC, one to stimulate islet regeneration following damage,
and a subsequent transplantation to support continued regeneration may be
more effective than a single dose.
The divergent mechanisms presented by freshly isolated UCB or BM-derived
ALDHhl mixed progenitor cells, and culture expanded BM-derived ALDH-purified
MSC, suggests a combinatorial cellular therapy may be the most effective
approach to islet regeneration and optimal glycémie control. MSC could be
administered to stimulate islet neogenesis and potentially protect newly formed
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islets from auto-immune destruction, followed by ALDHhl cell administration to
increase the size and vascularization of these newly formed islets. Further
understanding

of

the

specific

mechanisms

governing

these

divergent

endogenous regenerative programs will aid in the development of cellular
therapies to treat diabetes.
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